Pfizer (NYSE:PFE) Shares Acquired Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on March 06th, the Representative disclosed that they had bought between $1,001 and $15,000 in Pfizer stock on February 26th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Sterling Infrastructure (NASDAQ:STRL) on 3/3/2025.
• Purchased $1,001 – $15,000 in shares of Hillman Solutions (NASDAQ:HLMN) on 3/3/2025.
• Sold $1,001 – $15,000 in shares of Ford Motor (NYSE:F) on 2/26/2025.
• Purchased $1,001 – $15,000 in shares of Uber Technologies (NYSE:UBER) on 2/26/2025.
• Sold $15,001 – $50,000 in shares of UnitedHealth Group (NYSE:UNH) on 2/26/2025.
• Purchased $15,001 – $50,000 in shares of Microsoft (NASDAQ:MSFT) on 2/26/2025.
• Sold $1,001 – $15,000 in shares of General Motors (NYSE:GM) on 2/26/2025.
• Purchased $1,001 – $15,000 in shares of Tesla (NASDAQ:TSLA) on 2/26/2025.
• Sold $1,001 – $15,000 in shares of Akamai Technologies (NASDAQ:AKAM) on 2/26/2025.
• Sold $1,001 – $15,000 in shares of Danaher (NYSE:DHR) on 2/26/2025.

Pfizer Price Performance

Pfizer stock traded up $0.47 during midday trading on Friday, reaching $26.71. 54,320,707 shares of the stock traded hands, compared to its average volume of 39,797,473. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock’s fifty day moving average is $26.30 and its 200-day moving average is $27.25. The stock has a market cap of $151.35 billion, a P/E ratio of 18.94, a PEG ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same period in the prior year, the business posted $0.10 earnings per share. The company’s quarterly revenue was up 24.7% compared to the same quarter last year. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, March 7th. Investors of record on Friday, January 24th were paid a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, January 24th. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a yield of 6.44%. Pfizer’s dividend payout ratio is presently 121.99%.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Guggenheim reiterated a “buy” rating and issued a $33.00 price target on shares of Pfizer in a report on Monday, February 10th. Bank of America reiterated a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. Wolfe Research started coverage on Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target on the stock. Truist Financial reduced their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Finally, UBS Group reduced their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.06% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Retirement Wealth Solutions LLC acquired a new position in Pfizer in the fourth quarter valued at approximately $26,000. Rialto Wealth Management LLC acquired a new position in Pfizer in the fourth quarter valued at approximately $26,000. Clarity Asset Management Inc. purchased a new stake in Pfizer in the fourth quarter valued at approximately $27,000. Gould Capital LLC raised its position in Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 493 shares during the period. Finally, Gladius Capital Management LP raised its position in Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 38,015 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.